MedCity News reports that about 15% of patients who take their daily aspirin, as prescribed by their physician’s, have gastrointestinal problems as a result. That’s 3.6 million patients who need to seek an alternative to help them be adherent for the purposes of fending off cardiovascular disease.
A NASDAQ listed company, called Pozen, has developed a drug that has been studied in two double blind tests over two years and involved over 1,000 subjects.

The company says it’s looking for a larger drug distribution company to partner on this drug, which they describe as not having a big price tag.  The FDA will likely review the drug for approval in early 2013.